NIO752 Clinical Trials (2026): 2 Studies for Alzheimer Disease & Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 NIO752 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Alzheimer Disease & Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)) and 48 total planned enrollment. 1 NIO752 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT05469360 (Sep 2027).

Where to Participate: All NIO752 Trial Sites in the U.S. (1 site across 1 state)

Every actively recruiting NIO752trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
MOWashington University in St. LouisSt Louis63110NCT06372821Map

NIO752 clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingTotal
P1112

Recruiting NIO752 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT06372821NIO-SILKA Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILKP1Alzheimer Disease10Nov 2024

All NIO752 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05469360Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsP1active not recruiting38Novartis PharmaceuticalsFeb 2023
NCT06372821NIO-SILKA Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILKP1recruiting10University College, LondonNov 2024

NIO752 clinical trials: frequently asked questions

How many NIO752 clinical trials are there?
2 NIO752 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are NIO752 clinical trials recruiting in 2026?
Yes — 1 NIO752 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
What conditions is NIO752 being studied for?
NIO752 is being studied for Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Mild Cognitive Impairment. The trials are grouped by indication on this page.
What phase is NIO752 in?
NIO752 clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors NIO752 clinical trials?
The lead sponsor across the most NIO752 trials is Novartis Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming NIO752as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: